All fields are required.

Close Appointment form

BioServe Signs Distribution Deal with Merck Specialties Private Limited

BioServe Signs Distribution Deal with Merck Specialties Private Limited

January 9, 2007

Laurel, MD, January 9, 2007 –BioServe, a leading provider of rapid, economical processing and analyses of genomic content from biological samples, today announced a distribution deal with Merck Specialties Private Limited (MSPL), 100% Indian subsidiary of Merck KgaA. Under terms of the contract, MSPL will market and distribute BioServe’s genomic products and services, including DNA and RNA purification reagents, DNA sequencing, oligonucleotide synthesis and molecular biology teaching kits in India with plans to extend distribution coverage across Asia in 2007. This partnership will bolster MSPL’s genomics offering and gives BioServe expanded sales coverage across the Indian sub-continent.

“Merck is making use of the superlative quality of BioServe molecular research products to rapidly broaden our offerings,” said Mr. A. R. Bhattacharjee, Director – Chemicals, MSPL. “We are pleased to provide our customers with proven products to tackle a wide range of genomic challenges,” added Mr. Bhattacharjee.

For the past 15 years BioServe has been helping pharmaceutical, biotech and leading public research institutions accelerate their discovery programs with pioneering molecular research products and services. Built around core services spanning nucleic acid purification, DNA synthesis, DNA sequencing and genotyping, and a cutting-edge production facility in India, BioServe delivers a complete “biomaterial to validated data” genomics solution. Today BioServe’s serves over 600 customers across 20 countries benefiting from project turn-around times that are 50% faster than the industry norm. “BioServe’s partnership with MSPL will broaden the reach of our technology and services into laboratories worldwide, allowing us to better serve our customers,” said Rama Modali, President of BioServe Biotechnologies. “We look forward to building on the success achieved with scientists in basic research, drug discovery and development who trust the reliability of BioServe’s data compared to other quantitative approaches.”